NeoGenomics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company o...
Latest News
3 days ago · businesswire.com
Better Adds $43.7 Million in Volume Across Two Purchase-Focused Teams in California and the Mid-Atlantic Through NEO Home Loans ChannelNEW YORK--(BUSINESS WIRE)---- $BETR #BETR--Better Home & Finance Holding Company (NASDAQ: BETR) today announced that two established mortgage teams have joined NEO Home Loans, powered by Better. The Daniel Estrada Team is based in Bakersfield, California, and Team Neilsen serves Virginia, Washington, D.C., and Maryland. Both teams bring new purchase volume to Better and widen its reach in California's southern Central Valley and the Mid-Atlantic. The Daniel Estrada Team funded $23.7 million of mortgage vol.
5 days ago · globenewswire.com
FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster TrackDENVER, Nov. 11, 2026 (GLOBE NEWSWIRE) -- ( 247MarketNews ) — NeOnc Technologies Holdings (NASDAQ: NTHI) secured a Type B End-of-Phase meeting, scheduled for early January 2027, with the U.S. Food and Drug Administration (FDA), to discuss a potential accelerated approval pathway for its experimental intranasal brain cancer treatment NEO100, putting the company's regulatory strategy in focus as it prepares for a randomized Phase 3 study. NeOnc intends to seek FDA feedback on whether its existing clinical and nonclinical evidence could support a 505(b)(2) New Drug Application (NDA) seeking accelerated approval for recurrent or progressive IDH-mutant grade 4 astrocytoma.
5 days ago · globenewswire.com
NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100CALABASAS, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Type B End-of-Phase meeting to discuss a potential accelerated approval pathway for intranasal NEO100 in recurrent or progressive IDH-mutant grade 4 astrocytoma.
11 days ago · businesswire.com
NeoGenomics to Participate in Upcoming Investor ConferencesFORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Stephens Annual Investment Conference and the Piper Sandler 38th Annual Healthcare Conference.
15 days ago · globenewswire.com
NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-OncologyCALABASAS, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that data from its intranasal NEO100 and oral NEO212 programs will be presented in two posters on Friday, November 13, at the 31st Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), held November 12 to 15, 2026, at the Pennsylvania Convention Center in Philadelphia.
18 days ago · prnewswire.com
NEO Battery Reports Fiscal Year 2027 Second Quarter ResultsTORONTO, Oct. 29, 2026 /PRNewswire/ -- NEO Battery Materials Ltd. ("NEO" or the "Company") (TSXV: NBM) (OTC: NBMFF), a low-cost, silicon-enhanced battery manufacturer enabling high-performance capabilities for drones, robotics, and physical AI, today announced its financial and operational results for the second quarter ended August 31, 2026, and provided an update on its facility expansion, commercial pipeline, and growth initiatives.
19 days ago · marketbeat.com
What NeoGenomics (NEO) Said on Its Q3 Earnings CallNeoGenomics NASDAQ: NEO reported third-quarter revenue growth of 11% year over year, led by continued expansion in next-generation sequencing, or NGS, testing, while raising its full-year revenue and adjusted EBITDA guidance.
1 month ago · newsfilecorp.com
NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in FocusPediatric Case, Abu Dhabi Expansion and Board Appointment Highlight a Broader Development Strategy Houston, Texas--(Newsfile Corp. - October 16, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) is confronting one of the most consequential tests of its investigational brain-cancer platform as it pursues treatment options for patients facing some of the most difficult challenges in neuro-oncology. The company recently reported an early clinical update involving a critically ill three-year-old boy with an aggressive brain tumor who, after receiving investigational intranasal NEO100 through NeOnc's Compassionate Care program, is breathing independently without ventilator support and beginning to move his legs.
1 month ago · globenewswire.com
NeOnc's Boldest Test Yet: Child's Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use MilestoneDENVER, Oct. 16, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com ) -- NeOnc Technologies Holdings (NASDAQ: NTHI) delivered a deeply human clinical update that brings its investigational brain-cancer technology, expanding Abu Dhabi presence and high-profile banking appointment into sharper focus. The company reported that a critically ill three-year-old boy with an aggressive brain tumor is breathing independently without ventilator support and beginning to move his legs after receiving investigational intranasal NEO100 through NeOnc's Compassionate Care program.
1 month ago · globenewswire.com
NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu DhabiCALABASAS, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced early clinical improvement in its first patient treated in Abu Dhabi, United Arab Emirates, with investigational intranasal NEO100 through the Company's Compassionate Care program.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove NEO